A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue

Sung Jin Hong, Jin Seok Kim, Jong Hee Chang, Kyoung Min Kim, Soo Jeong Kim, Hye Won Lee, Jone Won Cheong, Seung Tae Lee, Yoo Hong Min

Research output: Contribution to journalArticle

11 Citations (Scopus)


The prognosis for patients with primary central nervous system (CNS) lymphoma (PCNSL) who relapse after the initial response is usually poor. A standard treatment for relapsed PCNSL has not yet been identified because of the heterogeneity of the therapies employed and the lack of large, prospective clinical trials. We describe a 46-year-old relapsed PCNSL patient who was successfully treated with intraventricular applications of rituximab to minimize neurotoxicity, 2 cycles of salvage chemotherapy with etoposide, ifosfamide, and cytarabine (VIA) regimen and high-dose chemotherapy with autologous stem cell rescue. The high-dose chemotherapy consisted of bischloroethylnitrosourea, etoposide, cytarabine, and melphalan (BEAM) regimen. Partial remission was detected after intraventricular rituximab therapy and the patient has been in complete remission without evidence of neurotoxicity for 28 months after high-dose chemotherapy with autologous stem cell rescue. This case indicates a new appropriate treatment guideline in relapsed PCNSL patient after initial intensive chemo-radiotherapy.

Original languageEnglish
Pages (from-to)280-283
Number of pages4
JournalYonsei medical journal
Issue number2
Publication statusPublished - 2009 Jun 11


All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this